Glutargin alkoclean is utilized to aid the management of symptoms associated with changes in metabolic balance, primarily resulting from alcohol intoxication. It is intended to provide supportive care in clinical situations where the body requires assistance in maintaining normal liver function during periods of stress. The medication may be considered to address discomfort and other signs related to acute alcohol consumption and certain forms of withdrawal.

Approved therapeutic applications include supporting symptomatic relief during acute alcohol intoxication and facilitating the body’s recovery from alcohol withdrawal syndrome.

Quick Fact: Supports temporary symptomatic relief related to intoxication.

The official regulatory profile for Glutargin alkoclean establishes strict eligibility rules based on the patient's medical history, age, and organ function. The medicine is primarily intended for use in adults for labeled indications.

---

Contraindicated Populations

Category	Official Regulatory Statement
Absolute Contraindication	Patients with known hypersensitivity to Arginine glutamate or any component.
Safety Exclusion	Use is not recommended in patients who have recently suffered a myocardial infarction (heart attack).

---

Restricted & Limited Use

Category	Official Regulatory Status
Age-Related	Use is not established in the pediatric population (children and adolescents).
Organ Function	Use requires caution in patients with severe renal impairment or severe hepatic impairment.
Procedural Status	Use must be stopped at least two weeks prior to scheduled surgery (may affect blood pressure).
Reproductive Status	Use during pregnancy and lactation is restricted due to insufficient safety data.

The official labeling limits use to individuals without these specific exclusions and mandates caution for those with certain conditions like severe organ impairment or metabolic disorders (e.g., Guanidinoacetate Methyltransferase deficiency).

Interactions with Other Medicines and Products

The interaction profile for Glutargin alkoclean is defined by documented pharmacodynamic effects and specific substance relationships that necessitate administration adjustments. All interaction information is based strictly on official government regulatory documentation.

Documented Drug and Substance Interactions

Co-administration with certain products may result in specific interaction outcomes as detailed in official prescribing information:

• Nitrate-Containing Medicines: Co-administration carries a potential for additive pharmacodynamic effects. This interaction is documented due to the medicine’s influence on the nitric oxide pathway, which may lead to a risk of hypotension.
• Iron-Containing Mineral Supplements: An interaction is documented due to the potential for binding or chelation between the active components, which may reduce the absorption of iron salts.
• Alcohol (Ethanol): The medicine has a formal substance interaction relationship with alcohol, necessary for its established role in the management of acute metabolic stress and toxic byproducts related to alcohol consumption.

Administration Timing Requirements

Administration of Glutargin alkoclean with specific mineral supplements requires mandatory temporal separation to avoid the documented reduction in absorption:

• Iron Salts: The official labeling requires that administration must be separated by a minimum of 2 hours from the intake of iron-containing mineral supplements.

Interaction Profile Classification

The overall profile does not include formal drug combinations classified as contraindicated in regulatory summaries. Interaction classifications are limited to clinically significant risks requiring precaution (additive pharmacodynamic effects) and binding interactions requiring mandatory timing adjustments.

Glutargin alkoclean is a combination product where L-arginine and L-glutamic acid are the key active components. Following absorption, the L-arginine moiety serves as a substrate for endothelial nitric oxide synthase (eNOS), facilitating the enzymatic conversion into nitric oxide (NO) and L-citrulline. The subsequent increase in NO concentration in the vascular endothelium acts as a signaling molecule, resulting in vasodilation at the systemic level.

Simultaneously, the L-glutamic acid component serves as a precursor for the synthesis of glutathione, a major endogenous antioxidant. This enhances the cellular capacity for the scavenging of reactive oxygen species (ROS) and contributes to the normalization of the antioxidant-prooxidant status, particularly within hepatocytes. The complex interaction of the amino acid components modulates cellular metabolism and supports the stability and functional integrity of hepatocyte membranes by inhibiting lipid peroxidation (LPO), which are intracellular consequences of oxidative stress. The overall systemic effect involves the modulation of vascular tone and the reinforcement of hepatic cellular protection against oxidative insults.

How Glutargin alkoclean is Used: Official Administration Guidelines

The administration of Glutargin alkoclean is defined by its official prescribing information, which standardizes the method of use for this Arginine glutamate compound. The overall use is typically confined to a short-term, supportive course, consistent with its classification as a detoxification agent.

---

Approved Route and Forms

Glutargin alkoclean is intended exclusively for oral intake. The medicine is available in two distinct official dosage forms for this purpose:

• Tablets (designed for direct swallowing).
• Powder for oral solution (intended for dissolution before ingestion).

Preparation Requirements

If the powder for oral solution form is used, it requires a mandatory dilution or reconstitution step. The sachet contents must be fully mixed with an appropriate volume of water or non-alcoholic liquid prior to administration to ensure the correct dose form and concentration is consumed. The tablets are administered without alteration.

---

Dosing Schedule and Patient Groups

The specific dosing schedule—including the frequency of intake, the exact amount per dose (e.g., 1 gram or 3 grams), and the total maximum daily amount—is determined by the official labeling provided with the medicine. This precise regimen is standardized to guide the proper use of the drug.

Official international regulatory summaries do not universally publish the specific numerical dosing for this regional product. Similarly, official age-group administration rules or dosage adjustments for individuals with organ impairment are governed by the detailed prescribing information from the regulating national medicines agency, rather than broad international guidance. Consultation of the product’s current authorized documentation is essential for these specific instructions.

Research Evidence / Overview of Studies for Glutargin alkoclean

Evidence for Use in Hyperammonemia Associated with Chronic Liver Diseases

Research for this indication primarily involved short-term Randomized Controlled Trials (RCTs) and related study designs. These studies monitored adult patients with chronic liver conditions, such as cirrhosis, who had documented elevated blood ammonia (hyperammonemia). Research explored the compound's potential to influence ammonia levels, monitoring direct changes in blood ammonia levels and specialized tests that track neuropsychiatric symptoms often associated with high ammonia.

Studies reported measurements of shifts in blood ammonia levels and described patterns of shifts in neuropsychiatric status when evaluated. However, long-term outcomes regarding sustained changes in chronic liver disease are not fully established, and comparative evidence against other supportive agents is sometimes mixed.

---

Evidence for Supportive Care in Acute Metabolic Stress

The evidence base consists mainly of Prospective Observational Studies and Translational Research examining temporary physiological imbalance in patients with acute alcohol intoxication or the initial phases of alcohol withdrawal syndrome. The outcomes that research examined were primarily related to neurotransmitter biomarkers in plasma and general, non-specific symptom scores. Studies report how symptoms evolved in the observed populations during the study period, often over very short observational windows (e.g., within hours).

The evidence is limited for this indication, as high-quality, large-scale RCTs specifically designed to assess clinical symptomatic relief are limited, and findings often rely on biomarker shifts rather than direct clinical endpoints.

---

Study Limitations and Evidence Gaps

Research for this compound is derived from studies with short-term follow-up, and data for long-term outcomes remain insufficient. The evidence level for hyperammonemia is generally considered Moderate, while the evidence for acute metabolic stress is generally graded as Low. Research has primarily focused on the general adult population, and data for certain groups—such as women who are pregnant or the pediatric population—remain insufficient. This highlights areas where more research is needed to fully characterize the compound’s research landscape.

Key Studies & References

1. WHO Anatomical Therapeutic Chemical (ATC) Classification System, 5th Level: A05BA01 (Arginine glutamate)
2. MedlinePlus Drug Information, Arginine Glutamate (NIH/NLM Guidance)

Common questions about Glutargin alkoclean (FAQ)

---

Q: Why is the word 'alkoclean' in the drug name?

The official role of the medicine is to assist the body's detoxification pathways by managing acute metabolic stress and toxic byproducts related to alcohol consumption. While regulatory documents do not explain the exact marketing name, the product's established purpose is consistent with the suggestion of support during metabolic stress.

---

Q: How quickly should I feel the effects of Glutargin alkoclean?

Glutargin alkoclean is primarily intended for short-term, supportive use during periods of acute metabolic stress. Research studies often observe patient outcomes over very short observational windows, sometimes over the course of hours. This type of research design is consistent with an intention to provide support for acute metabolic issues.

---

Q: How long does the effect of Glutargin alkoclean last in the body?

The medicine is approved for short-term, supportive courses, meaning it is not designed for continuous long-term use. The medicine’s approval for a short-term course suggests its intended therapeutic effect after a single intake is temporary. The precise pharmacokinetic duration is not consistently published in general regulatory summaries.

---

Q: Is Glutargin alkoclean a vitamin or a medication?

Glutargin alkoclean is classified as a medicinal product within the pharmacological class of liver therapy, not a vitamin or dietary supplement. Its active substance, Arginine glutamate, is an amino acid salt derived from components essential to human biochemistry.

---

Q: Can Glutargin alkoclean be taken every day?

According to official administration guidelines, the overall use of this medicine is typically confined to a short-term, supportive course, rather than indefinite daily use. The medicine is generally approved only for a limited course of use, and the precise regimen is defined by the official labeling.

---

Q: Does Glutargin alkoclean make you drowsy or tired?

Official regulatory documents categorize side effects by frequency and body system. The commonly or uncommonly reported adverse reactions listed do not include drowsiness or tiredness.

---

Q: Can Glutargin alkoclean be taken with pain relievers like paracetamol?

Official regulatory documents do not list a formal interaction with pain relievers such as paracetamol (acetaminophen). The documented interactions listed are limited to Nitrate-Containing Medicines, Iron-Containing Mineral Supplements, and Alcohol.

---

Q: What should older adults be aware of when considering Glutargin alkoclean?

Official information advises caution for older adults. This caution is noted due to the potential for hypotension (low blood pressure), which is listed as a serious adverse reaction of the medicine.

---

Q: Are there any food or drinks that should be avoided when taking Glutargin alkoclean?

Yes, regulatory information indicates a formal interaction with alcohol (ethanol). Additionally, the absorption of iron-containing mineral supplements may be reduced if intake is not separated from the medicine by at least 2 hours.

---

Q: Does Glutargin alkoclean affect kidney function?

Use is contraindicated (must not be used) in individuals with severe kidney dysfunction. Caution is also advised for patients with impaired kidney function due to the potential for hyperkalemia (high blood potassium level), and monitoring may be required.

---

Q: Does Glutargin alkoclean contain any alcohol itself?

The medicine's active component is Arginine glutamate, which is an amino acid salt. It is classified as a detoxification agent and is used to manage toxic byproducts related to alcohol consumption, but the composition itself does not contain alcohol.

---

Q: What is the intended duration of a course of Glutargin alkoclean?

The official administration guidelines indicate that the use of Glutargin alkoclean is generally confined to a short-term, supportive course. It is not intended for continuous, long-term administration.

---

Q: Are there drug-drug interactions listed for Glutargin alkoclean?

Yes, documented interactions exist. These include co-administration with Nitrate-Containing Medicines, which may carry an increased risk of hypotension. An interaction with Iron-Containing Mineral Supplements may also reduce their absorption.

---

Q: Is the absorption of Glutargin alkoclean affected by food?

Official documents require separation from iron-containing mineral supplements by at least two hours to avoid reduced absorption. No general instructions are provided regarding how typical food intake affects the absorption of the medicine.

---

Q: Is it better to take Glutargin alkoclean in the morning or evening?

General regulatory summaries do not specify a preference for taking the medicine in the morning or evening. The precise dosing schedule, including the time of day, is determined by the official prescribing information specific to its use.

---

Q: Are there any warnings about using heavy machinery after taking Glutargin alkoclean?

Regulatory warnings are primarily focused on the risk of hypotension (low blood pressure) and electrolyte imbalances. However, the official summaries do not contain an explicit warning about operating heavy machinery or driving after administration.

---

Q: What is the shelf life of Glutargin alkoclean?

The medicine has a shelf life of 2 years. To maintain its stability and safety, it must be stored correctly, typically at or below 25 C in the original packaging.

---

Q: Does taking Glutargin alkoclean require any dietary restrictions?

Yes, two specific substances are noted. The consumption of alcohol is a formal interaction. Additionally, the intake of iron-containing mineral supplements requires a 2-hour separation from the medicine.

---

Q: Can Glutargin alkoclean be crushed or split?

The tablets are manufactured for direct swallowing and are administered without alteration. The powder form requires mandatory dissolution in water or a non-alcoholic liquid prior to ingestion to ensure the correct dose form is consumed.

---

Q: Can pregnant or breastfeeding women use Glutargin alkoclean?

Use during pregnancy and lactation is restricted according to official guidelines. This restriction is due to insufficient safety data for these populations.

---

Q: Can children or adolescents use Glutargin alkoclean?

The medicine is primarily intended for use in adults for its labeled indications. Use is not established in the pediatric population (children and adolescents) due to insufficient safety data.

How to Store and Dispose of Glutargin alkoclean

The storage of Glutargin alkoclean (powder for oral solution) is strictly governed by the conditions defined in the official regulatory labeling to ensure product stability and safety. The medicine must be stored at a temperature that does not exceed 25°C (seventy-seven degrees Fahrenheit).

Required Storage and Stability

Requirement	Condition
Temperature Limit	Store at or below 25 C
Packaging	Keep in the original packaging
Shelf-Life	2 years (when stored correctly)

For child safety, the medicine must be kept out of reach of children. No specific instructions for disposal are detailed in the official labeling; therefore, unused or expired product should be discarded in accordance with all applicable local pharmaceutical waste regulations.